May 15, 2024 07:12 AM EDTUpdated 07:24 AM

Bolt Biotherapeutics revamps as it drops lead cancer asset, changes CEO and trims headcount

Bolt Biotherapeutics is reshuffling to cut costs and extend its cash runway to the second half of 2026.

The California biotech

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bolt Bio­ther­a­peu­tics re­vamps as it drops lead can­cer as­set, changes CEO and trims head­count